-
251.发明公开
公开(公告)号：KR1020130125736A
公开(公告)日：2013-11-19
申请号：KR1020130052669
申请日：2013-05-09
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/122 , A61P29/00
Abstract: The present invention relates to a composition containing coenzyme Q10 as an active ingredient for preventing or treating inflammatory diseases or immune rejection. More particularly, coenzyme Q10 suppresses or reduces the activity of Th17 and effectively promotes or enhances the activity of regulatory T cells (Treg), thereby being used as a composition for preventing or treating immune rejection such as graft rejection or inflammatory diseases. In addition, coenzyme Q10 does not cause cytotoxicity and the side effects to the drug is not toxic, thereby being safely administered in the long-term and being stable in the body.
Abstract translation: 本发明涉及含有辅酶Q10作为预防或治疗炎性疾病或免疫排斥的活性成分的组合物。 更具体地，辅酶Q10抑制或降低Th17的活性，并且有效地促进或增强调节性T细胞（Treg）的活性，从而被用作预防或治疗免疫排斥反应例如移植排斥或炎性疾病的组合物。 此外，辅酶Q10不会引起细胞毒性，对药物的副作用是无毒性的，因此长期安全施用并且在体内稳定。
-
公开(公告)号：KR1020130125569A
公开(公告)日：2013-11-19
申请号：KR1020120049198
申请日：2012-05-09
Applicant: 가톨릭대학교 산학협력단
IPC: C12N5/0775 , C12N5/02 , A61K35/12
CPC classification number: C12N5/0668
Abstract: The present invention relates to a method for isolating mesenchymal stem cells from synovial fluid and, more specifically, to a method for isolating and culturing mesenchymal stem cells from synovial fluid of an individual with immune disease; a composition containing the isolated mesenchymal stem cells as active ingredients for preventing and treating immune diseases; and a cell therapeutic agent containing the synovial fluid-derived mesenchymal stem cells as active ingredients for preventing and treating rheumatoid arthritis. The synovial fluid-derived mesenchymal stem cells in the present invention are isolated from an individual with immune diseases. The synovial fluid-derived mesenchymal stem cells reduce abnormal regulation of immune responses such as transplantation rejection, which are an existing problem when the synovial fluid-derived mesenchymal stem cells are used as a cell therapeutic agent, thereby obtaining effective and safe treatment effects.
Abstract translation: 本发明涉及从滑液中分离间充质干细胞的方法，更具体地说，涉及从具有免疫疾病的个体的滑液中分离和培养间充质干细胞的方法; 含有分离的间充质干细胞作为预防和治疗免疫疾病的活性成分的组合物; 以及含有滑膜液间充质干细胞作为预防和治疗类风湿性关节炎的活性成分的细胞治疗剂。 从具有免疫疾病的个体中分离本发明中的滑液来源的间充质干细胞。 滑膜液间充质干细胞减少免疫应答的异常调节，如移植排斥反应，这是使用滑膜液间充质干细胞作为细胞治疗剂时存在的问题，从而获得有效和安全的治疗效果。
-
公开(公告)号：KR1020130121740A
公开(公告)日：2013-11-06
申请号：KR1020130045824
申请日：2013-04-25
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/192 , A61K31/185 , A61K31/20 , A61P37/00
CPC classification number: A61K31/192
Abstract: The present invention relates to a composition containing SR11302 as an active ingredient for preventing or treating immune diseases and, more specifically, to a composition containing SR11302 or a pharmaceutically acceptable salt thereof as an active ingredient for preventing or treating immune diseases. The compounds according to the present invention effectively suppresses the differentiation of cytotoxic Th17 cells which produces and secretes inflammatory cytokines and enhances the activity of regulatory T cells (Treg) which suppresses the function of abnormally activated immunocytes and controls inflammation, thereby being used as a pharmaceutical composition or an immunosuppressor for preventing or treating autoimmune diseases, inflammatory diseases, and immune diseases such as transplant rejection, caused by various abnormal immune responses.
Abstract translation: 本发明涉及含有SR11302作为预防或治疗免疫疾病的活性成分的组合物，更具体地，涉及含有SR11302或其药学上可接受的盐作为预防或治疗免疫疾病的活性成分的组合物。 根据本发明的化合物有效地抑制了产生和分泌炎性细胞因子的细胞毒性Th17细胞的分化，并增强了调节性T细胞（Treg）的活性，其抑制异常活化的免疫细胞的功能并控制炎症，从而被用作药物 组合物或免疫抑制剂，用于预防或治疗由各种异常免疫应答引起的自身免疫性疾病，炎性疾病和免疫疾病如移植排斥反应。
-
公开(公告)号：KR1020130116825A
公开(公告)日：2013-10-24
申请号：KR1020130041359
申请日：2013-04-16
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/4704 , A61K38/17 , C12N15/63 , C12N15/12
CPC classification number: A61K31/353 , A61K38/1709 , Y10S514/825
Abstract: PURPOSE: An antioxidant is provided to effectively enhance the expression of Rcan3 gene and to be used as an immunosuppressive agent for treating or preventing immune diseases because Rcan3 protein suppresses calcineurin pathway. CONSTITUTION: An antioxidant increases the expression of Rcan3 gene. The antioxidant is rebamipide or polyphenol compounds. The polyphenol compounds are proanthocyanidin. A method for increasing the expression of Rcan3 in vitro comprises the step of treating cells with the antioxidant. A composition for preventing or treating immune disease contains Rcan3 gene or protein as an active ingredient.
Abstract translation: 目的：提供抗氧化剂以有效增强Rcan3基因的表达，并用作免疫抑制剂，用于治疗或预防免疫疾病，因为Rcan3蛋白抑制钙调神经磷酸酶途径。 构成：抗氧化剂增加Rcan3基因的表达。 抗氧化剂是瑞巴派特或多酚化合物。 多酚化合物是原花色素。 在体外增加Rcan3表达的方法包括用抗氧化剂处理细胞的步骤。 用于预防或治疗免疫疾病的组合物含有Rcan3基因或蛋白质作为活性成分。
-
公开(公告)号：KR1020130110283A
公开(公告)日：2013-10-10
申请号：KR1020120032089
申请日：2012-03-29
Applicant: 가톨릭대학교 산학협력단
IPC: A61K39/395 , A61P37/00
Abstract: PURPOSE: A composition containing regulatory T cells for treating autoimmune diseases is provided to promote the generation of regulatory B cells and to suppress activation of antibody producing B cells, thereby treating immune diseases including autoimmune diseases. CONSTITUTION: A composition for treating autoimmune diseases contains regulatory T cells. The composition promotes generation of regulatory B cells and suppresses the activation of antibody producing B cells. The regulatory T cells are autologous. The regulatory T cells include natural regulatory T cells and adaptive regulatory T cells. The regulatory T cells are differentiated by anti-CD3 and anti-CD28 antibodies and TGF-beta.
Abstract translation: 目的：提供含有用于治疗自身免疫疾病的调节性T细胞的组合物，以促进调节性B细胞的产生并抑制产生抗体的B细胞的活化，从而治疗包括自身免疫疾病在内的免疫疾病。 构成：用于治疗自身免疫性疾病的组合物含有调节性T细胞。 该组合物促进调节性B细胞的产生并抑制产生抗体的B细胞的活化。 调节性T细胞是自体的。 调节性T细胞包括天然调节性T细胞和适应性调节性T细胞。 调节性T细胞被抗CD3和抗CD28抗体和TGF-β分化。
-
Patent Agency Ranking
公开(公告)号：KR1020130106786A
公开(公告)日：2013-09-30
申请号：KR1020130028982
申请日：2013-03-19
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/4704 , A61K35/28 , A61P37/00
CPC classification number: A61K31/4704 , A61K35/28 , Y10S514/825 , Y10S514/885 , Y10S514/886
Abstract: PURPOSE: A composition for preventing or treating immunization disease including bone marrow-derived suppressor cell and rebamipide effectively treats immunization reaction and inflammation, by reducing the level of an autoimmune antibody and accelerating the activation of immunodulatory T cells. CONSTITUTION: A composition for preventing or treating immunization disease includes bone marrow-derived suppressor cell and rebamipide. The marrow-derived suppressor cell and rebamipide accelerates or increase the activity of Regulatory T cell: Treg and decrease the concentration of IgG, IgG1, and lgG2a in blood. The marrow-derived suppressor cell and rebamipide reduces and suppress the expression of IL-17 which is the inflammatory cytokine. The composition includes 5x10^5-2x10^6 of the marrow-derived suppressor cells.
Abstract translation: 目的：用于预防或治疗免疫疾病的组合物，包括骨髓来源的抑制细胞和瑞巴派特，通过降低自身免疫抗体的水平并加速免疫调节T细胞的活化，有效治疗免疫反应和炎症。 构成：用于预防或治疗免疫疾病的组合物包括骨髓来源的抑制细胞和瑞巴派特。 骨髓来源的抑制细胞和雷巴米特加速或增加调节性T细胞：Treg的活性，并降低血液中IgG，IgG1和IgG2a的浓度。 骨髓来源的抑制细胞和瑞巴派汀可降低和抑制炎性细胞因子IL-17的表达。 该组合物包括5×10 5〜2×10 -6个骨髓来源的抑制细胞。
-
公开(公告)号：KR1020130044155A
公开(公告)日：2013-05-02
申请号：KR1020120114823
申请日：2012-10-16
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/4704 , A61P3/04 , A61P3/00
CPC classification number: A61K31/4704 , A23L33/10 , A23V2002/00 , A61K9/0019 , A23V2200/332
Abstract: PURPOSE: Obesity preventing or treating composition comprising rebamipide is provided to reduce LDL cholesterol levels and to increase HDL cholesterol levels. CONSTITUTION: Obesity preventing or treating composition comprising rebamipide comprises rebamipide compounds or salt of the rebamipide compounds. Rebamipide is capable of reducing weight, fat cells, total cholesterol levels, glucose and LDL cholesterol levels. Rebamipide has anti-obesity activiation through an action of changing white fat into brown fat. Rebamipide increases the activation of amplification of a regulatory T cell.
Abstract translation: 目的：提供包含瑞巴派特的肥胖症预防或治疗组合物以降低LDL胆固醇水平和提高HDL胆固醇水平。 构成：包含瑞巴派特的肥胖症预防或治疗组合物包括雷巴米特化合物或雷巴米特化合物的盐。 瑞巴米特能够减轻体重，脂肪细胞，总胆固醇水平，葡萄糖和低密度脂蛋白胆固醇水平。 瑞巴米特通过将白脂肪变成棕色脂肪的作用，具有抗肥胖作用。 瑞巴米特可增加调节性T细胞扩增的活化。
-
公开(公告)号：KR1020130015337A
公开(公告)日：2013-02-14
申请号：KR1020110077275
申请日：2011-08-03
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K9/127 , A61K9/1277 , A61K47/68 , Y10S977/915
Abstract: PURPOSE: An immunotherapeutic agent of a nanosome form containing a cell suspension and abatacept is provided to ensure a high transmission rate of abatacept into a target site and to effectively suppress TNF-alpha and IL-17 generation. CONSTITUTION: An immunotherapeutic agent of a nanosome form contains a cell suspension and abatacept. A composition for preventing or treating immune diseases contains the immunotherapeutic agent. A method for manufacturing the immunotherapeutic agent comprises: a step of suspending macrophage; a step of passing the suspension solution through a membrane filter; a step of adding abatacept to the solution; and a step of isolating the immunotherapeutic agent from the solution. The macrophage is suspended in a PBS solution in a concentration of 1x10^6 to 1x10^7 cells/ml.
Abstract translation: 目的：提供含有细胞悬浮液和abatacept的纳米体形式的免疫治疗剂，以确保abatacept的高透射率进入靶位点，并有效抑制TNF-α和IL-17的产生。 构成：纳米颗粒形式的免疫治疗剂含有细胞悬浮液和阿巴西普（abatacept）。 用于预防或治疗免疫疾病的组合物含有免疫治疗剂。 制备免疫治疗剂的方法包括：悬浮巨噬细胞的步骤; 使悬浮液通过膜过滤器的步骤; 将abatacept加入到溶液中的步骤; 以及从溶液中分离免疫治疗剂的步骤。 将巨噬细胞以1×10 6至1×10 7细胞/ ml的浓度悬浮于PBS溶液中。
-
公开(公告)号：KR101215670B1
公开(公告)日：2012-12-26
申请号：KR1020110010999
申请日：2011-02-08
Applicant: 가톨릭대학교 산학협력단
IPC: A61K38/16 , A61K31/7105 , A61P29/00 , A61P37/00
Abstract: 본발명은 Grim19을유효성분으로함유하는면역질환의예방또는치료용조성물에관한것으로서, 보다구체적으로본 발명은 Grim19 단백질을유효성분으로함유하는면역질환의예방또는치료용조성물, 면역억제용조성물, Grim19 단백질을이용한미분화 T 세포의 Th17 세포로의분화를감소또는억제하는방법및 조절 T 세포를활성화시키는방법에관한것이다. 본발명에따른상기 Grim19은염증성사이토카인을생성및 분비하는세포독성 Th17 세포의분화를억제하는효과가우수하고, 비정상적으로활성화된면역세포의기능을억제하고염증반응을제어하는특성을갖는면역조절 T 세포(Treg)는활성화시키는효과가우수하므로면역반응의조절이상으로유발되는자가면역질환, 염증성질환및 이식거부질환과같은면역질환을예방또는치료할수 있는약학적조성물또는면역억제제로유용하게사용할수 있다.
-
公开(公告)号：KR1020120129121A
公开(公告)日：2012-11-28
申请号：KR1020110047181
申请日：2011-05-19
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/519 , A61K31/505 , A61K9/127 , A61P29/00
CPC classification number: A61K31/519 , A61K9/127 , A61K31/505 , C12N5/06 , C12N5/0645
Abstract: PURPOSE: An immunotherapeutic agent containing a cell suspension and methotrexate is provided to enhance methotrexate transfer rate to a target site and to effectively suppress TNF-alpha generation. CONSTITUTION: An immunotherapeutic agent of a nanosome form contains a cell suspension and methotrexate. The cell suspension is a cell membrane in cell lysate. A composition for preventing or treating immune diseases contains an immunotherapeutic agent. The immune diseases are autoimmune diseases, inflammatory diseases, or cell, tissue, or organ transplantation rejection. [Reference numerals] (AA) MTX-containing nanosome
Abstract translation: 目的：提供含有细胞悬浮液和甲氨蝶呤的免疫治疗剂，以增强甲氨蝶呤转移到靶位点并有效抑制TNF-α的产生。 构成：纳米体形式的免疫治疗剂含有细胞悬浮液和甲氨蝶呤。 细胞悬浮液是细胞裂解液中的细胞膜。 用于预防或治疗免疫疾病的组合物含有免疫治疗剂。 免疫疾病是自身免疫性疾病，炎性疾病或细胞，组织或器官移植排斥反应。 （AA）含MTX的纳米体
-
-
-
-
-
-
-
-
-
Search Results
262
records
(took 0.035 seconds)
